• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

酪氨酸磷酸酶Shp2与NPM-ALK相互作用并调节间变性淋巴瘤细胞的生长和迁移。

The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration.

作者信息

Voena Claudia, Conte Chiara, Ambrogio Chiara, Boeri Erba Elisabetta, Boccalatte Francesco, Mohammed Shabaz, Jensen Ole N, Palestro Giorgio, Inghirami Giorgio, Chiarle Roberto

机构信息

Department of Biomedical Sciences and Human Oncology, University of Turin, Turin, Italy.

出版信息

Cancer Res. 2007 May 1;67(9):4278-86. doi: 10.1158/0008-5472.CAN-06-4350.

DOI:10.1158/0008-5472.CAN-06-4350
PMID:17483340
Abstract

Anaplastic large cell lymphomas (ALCL) are mainly characterized by the reciprocal translocation t(2;5)(p23;q35) that involves the anaplastic lymphoma kinase (ALK) gene and generates the fusion protein NPM-ALK with intrinsic tyrosine kinase activity. NPM-ALK triggers several signaling cascades, leading to increased cell growth, resistance to apoptosis, and changes in morphology and migration of transformed cells. To search for new NPM-ALK interacting molecules, we developed a mass spectrometry-based proteomic approach in HEK293 cells expressing an inducible NPM-ALK and identified the tyrosine phosphatase Shp2 as a candidate substrate. We found that NPM-ALK was able to bind Shp2 in coprecipitation experiments and to induce its phosphorylation in the tyrosine residues Y542 and Y580 both in HEK293 cells and ALCL cell lines. In primary lymphomas, antibodies against the phosphorylated tyrosine Y542 of Shp2 mainly stained ALK-positive cells. In ALCL cell lines, Shp2-constitutive phosphorylation was dependent on NPM-ALK, as it significantly decreased after short hairpin RNA (shRNA)-mediated NPM-ALK knock down. In addition, only the constitutively active NPM-ALK, but not the kinase dead NPM-ALK(K210R), formed a complex with Shp2, Gab2, and growth factor receptor binding protein 2 (Grb2), where Grb2 bound to the phosphorylated Shp2 through its SH2 domain. Shp2 knock down by specific shRNA decreased the phosphorylation of extracellular signal-regulated kinase 1/2 and of the tyrosine residue Y416 in the activation loop of Src, resulting in impaired ALCL cell proliferation and growth disadvantage. Finally, migration of ALCL cells was reduced by Shp2 shRNA. These findings show a direct involvement of Shp2 in NPM-ALK lymphomagenesis, highlighting its critical role in lymphoma cell proliferation and migration.

摘要

间变性大细胞淋巴瘤(ALCL)主要特征是2号染色体和5号染色体发生相互易位t(2;5)(p23;q35),该易位涉及间变性淋巴瘤激酶(ALK)基因,并产生具有内在酪氨酸激酶活性的融合蛋白NPM-ALK。NPM-ALK触发多个信号级联反应,导致细胞生长增加、抗凋亡能力增强以及转化细胞的形态和迁移发生改变。为了寻找新的与NPM-ALK相互作用的分子,我们在表达可诱导NPM-ALK的HEK293细胞中开发了一种基于质谱的蛋白质组学方法,并鉴定酪氨酸磷酸酶Shp2为候选底物。我们发现在共沉淀实验中NPM-ALK能够结合Shp2,并在HEK293细胞和ALCL细胞系中诱导其酪氨酸残基Y542和Y580发生磷酸化。在原发性淋巴瘤中,针对Shp2磷酸化酪氨酸Y542的抗体主要染色ALK阳性细胞。在ALCL细胞系中,Shp2的组成型磷酸化依赖于NPM-ALK,因为在短发夹RNA(shRNA)介导的NPM-ALK敲低后其显著降低。此外,只有组成型活性NPM-ALK,而不是激酶失活的NPM-ALK(K210R),与Shp2、Gab2和生长因子受体结合蛋白2(Grb2)形成复合物,其中Grb2通过其SH2结构域结合磷酸化的Shp2。通过特异性shRNA敲低Shp2可降低细胞外信号调节激酶1/2以及Src激活环中酪氨酸残基Y416的磷酸化,导致ALCL细胞增殖受损和生长劣势。最后,Shp2 shRNA可减少ALCL细胞的迁移。这些发现表明Shp2直接参与NPM-ALK淋巴瘤的发生,突出了其在淋巴瘤细胞增殖和迁移中的关键作用。

相似文献

1
The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration.酪氨酸磷酸酶Shp2与NPM-ALK相互作用并调节间变性淋巴瘤细胞的生长和迁移。
Cancer Res. 2007 May 1;67(9):4278-86. doi: 10.1158/0008-5472.CAN-06-4350.
2
Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth.Grb2 衔接蛋白在核磷蛋白-间变性淋巴瘤激酶(NPM-ALK)介导的信号转导和间变大细胞淋巴瘤生长中的作用。
J Biol Chem. 2010 Aug 20;285(34):26441-50. doi: 10.1074/jbc.M110.116327. Epub 2010 Jun 16.
3
The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.间变性大细胞淋巴瘤中CD30的表达由核磷蛋白-间变性淋巴瘤激酶以细胞类型特异性方式介导的JunB水平调控。
Cancer Res. 2006 Sep 15;66(18):9002-8. doi: 10.1158/0008-5472.CAN-05-4101.
4
Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.核磷蛋白-间变性淋巴瘤激酶(NPM-ALK),一种新型的热休克蛋白90(Hsp90)底物酪氨酸激酶:热休克蛋白90拮抗剂17-烯丙基氨基-17-去甲氧基格尔德霉素对ALK(+) CD30(+)淋巴瘤细胞中NPM-ALK表达及酪氨酸磷酸化的下调作用
Cancer Res. 2002 Mar 1;62(5):1559-66.
5
SHP1 tyrosine phosphatase negatively regulates NPM-ALK tyrosine kinase signaling.SHP1 酪氨酸磷酸酶负向调节 NPM-ALK 酪氨酸激酶信号传导。
Blood. 2006 May 15;107(10):4130-8. doi: 10.1182/blood-2005-06-2421. Epub 2006 Feb 9.
6
Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.雷帕霉素哺乳动物靶点信号通路的激活有助于间变性淋巴瘤激酶阳性间变性大细胞淋巴瘤中的肿瘤细胞存活。
Cancer Res. 2006 Jul 1;66(13):6589-97. doi: 10.1158/0008-5472.CAN-05-3018.
7
Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma.SHP1的缺失增强了JAK3/STAT3信号传导,并减少了ALK阳性间变性大细胞淋巴瘤中JAK3和NPM-ALK的蛋白酶体降解。
Blood. 2006 Oct 15;108(8):2796-803. doi: 10.1182/blood-2006-04-017434. Epub 2006 Jul 6.
8
Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.间变性大细胞淋巴瘤及其他淋巴瘤中NPM-ALK和变异融合基因的病理生物学
Leukemia. 2000 Sep;14(9):1533-59. doi: 10.1038/sj.leu.2401878.
9
p130Cas mediates the transforming properties of the anaplastic lymphoma kinase.p130Cas介导间变性淋巴瘤激酶的转化特性。
Blood. 2005 Dec 1;106(12):3907-16. doi: 10.1182/blood-2005-03-1204. Epub 2005 Aug 16.
10
NPM/ALK downregulates p27Kip1 in a PI-3K-dependent manner.NPM/ALK以PI-3K依赖的方式下调p27Kip1。
Exp Hematol. 2004 Dec;32(12):1265-71. doi: 10.1016/j.exphem.2004.11.002.

引用本文的文献

1
ALK in cancer: from function to therapeutic targeting.癌症中的间变性淋巴瘤激酶:从功能到治疗靶点
Nat Rev Cancer. 2025 May;25(5):359-378. doi: 10.1038/s41568-025-00797-9. Epub 2025 Mar 7.
2
Targeting Protein Tyrosine Phosphatases to Improve Cancer Immunotherapies.靶向蛋白酪氨酸磷酸酶以改善癌症免疫疗法。
Cells. 2024 Jan 25;13(3):231. doi: 10.3390/cells13030231.
3
SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment.SHP2:癌症及其微环境界面的多功能靶点。
Cancer Discov. 2023 Nov 1;13(11):2339-2355. doi: 10.1158/2159-8290.CD-23-0383.
4
Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma.靶向 CCR7-PI3Kγ 克服 ALK 重排淋巴瘤对酪氨酸激酶抑制剂的耐药性。
Sci Transl Med. 2023 Jun 28;15(702):eabo3826. doi: 10.1126/scitranslmed.abo3826.
5
Obesity and Risk for Lymphoma: Possible Role of Leptin.肥胖与淋巴瘤风险:瘦素的可能作用。
Int J Mol Sci. 2022 Dec 8;23(24):15530. doi: 10.3390/ijms232415530.
6
A pan-cancer analysis confirms PTPN11's potential as a prognostic and immunological biomarker.泛癌分析证实 PTPN11 有作为预后和免疫生物标志物的潜力。
Aging (Albany NY). 2022 Jul 8;14(13):5590-5610. doi: 10.18632/aging.204171.
7
Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma.酪氨酸磷酸酶调节 ALK+间变大细胞淋巴瘤对 ALK 抑制剂的耐药性。
Blood. 2022 Feb 3;139(5):717-731. doi: 10.1182/blood.2020008136.
8
Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects.ALK 的药理学抑制剂通过靶标作用诱导免疫原性细胞死亡。
Cell Death Dis. 2021 Jul 16;12(8):713. doi: 10.1038/s41419-021-03997-x.
9
Activating Mutation of SHP2 Establishes a Tumorigenic Phonotype Through Cell-Autonomous and Non-Cell-Autonomous Mechanisms.SHP2的激活突变通过细胞自主和非细胞自主机制建立致瘤表型。
Front Cell Dev Biol. 2021 Mar 11;9:630712. doi: 10.3389/fcell.2021.630712. eCollection 2021.
10
Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance.第三代EGFR TKI耐药中全球蛋白质组和磷酸化蛋白质组的改变揭示了规避耐药的药物靶点。
Cancer Res. 2021 Jun 1;81(11):3051-3066. doi: 10.1158/0008-5472.CAN-20-2435. Epub 2021 Mar 16.